Nakagawa T, Kawamura T, Matsumura Y, Yoshikawa Y, Takada K, Ike O, Wada H, Hitomi S
Department of Pharmaceutics and Pharmacokinetics, Kyoto Pharmaceutical University.
Nihon Rinsho. 1998 Mar;56(3):680-5.
As compared to the conventional standard chemotherapy of solid cancer such as lung, biochemical modulation (BCM) therapy has been proven to have a good therapeutic efficiency. BCM therapy uses the low dose and low infusion rate of anti-cancer drug. To increase of the QOL of cancer patients, oral BCM therapy is needed. For this purpose, two kinds of new oral sustained-release cisplatin preparations were developed, micro-porous CDDP capsule made of ethylcellulose(EC) and CDDP-EC-stearic acid solid dispersion. After oral administrations of these preparations, serum CDDP levels were maintained over 0.2 microgram/ml for 24h. Experimental therapy using P815 tumor cells transplanted mice suggested the usefulness of CDDP solid dispersion preparation.
与肺癌等实体癌的传统标准化疗相比，生物化学调节（BCM）疗法已被证明具有良好的治疗效果。BCM疗法采用低剂量、低输注速率的抗癌药物。为提高癌症患者的生活质量，需要口服BCM疗法。为此，研发了两种新型口服顺铂缓释制剂，即由乙基纤维素（EC）制成的微孔顺铂胶囊和CDDP-EC-硬脂酸固体分散体。口服这些制剂后，血清顺铂水平在24小时内维持在0.2微克/毫升以上。使用移植了P815肿瘤细胞的小鼠进行的实验治疗表明，CDDP固体分散体制剂具有有效性。
